Drug
Dnl919
Dnl919: highest development phase Phase 1, developed by Denali Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Denali Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| DNL919 NCT05450549 | Phase 1 | Healthy Participant |
Latest
No recent events.
Follow Dnl919 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.